Peripheral detection of EGFR status in lung cancer patients
Research type
Research Study
Full title
Testing of clinical samples with a microfluidic-based methodology for rapid detection of epidermal growth factor mutations in blood from patients with lung cancer
IRAS ID
221641
Contact name
Michael J Lind
Contact email
Sponsor organisation
Hull & East Yorkshire Hospitals NHS Trust
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Lung cancer remains the biggest killer from malignant disease in the UK. 10% patients with lung cancer have a mutation in the epidermal growth factor receptor (EGFR), a protein present on the surface of lung cancer cells. These patients respond better to a class of drugs called receptor tyrosine kinase inhibitors, rather than conventional chemotherapy. Conversely, patients who do not have these mutations do better with the conventional drugs. This project aims to evaluate a new type of analysis to detect EGFR mutations based on tumour cells circulating in the blood, removing the need for a patient to have an invasive operation.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
17/NE/0076
Date of REC Opinion
9 Mar 2017
REC opinion
Favourable Opinion